Want to join the conversation?
$MNK said it confirmed enrollment of the first patient in its Phase 3 clinical study to evaluate the efficacy and safety of terlipressin (for injection) in subjects with Hepatorenal Syndrome (HRS) type 1. HRS is a rare syndrome of marked renal dysfunction in patients with cirrhosis, decompensated liver disease and portal hypertension.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.